Your session is about to expire
← Back to Search
ABC008 for Inclusion Body Myositis
Study Summary
This trial tests a new drug to see if it can treat Inclusion Body Myositis, a muscle disorder. It is a big, carefully designed study to see how safe and effective the drug is.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can walk 3 meters and sit down by myself, using aids if needed but without another person's help.I have been diagnosed with IBM as per ENMC criteria and have histopathology results.I have a condition that makes it hard to measure my muscle strength or do physical tests.I am over 40 years old.My weight is between 40 and 150 kg.I can get up from a chair using my arms but without help or a device.I have an autoimmune disease but it's not severe and under control.I do not have any muscle conditions other than IBM.I can get up from a chair using my arms but without help or a device.My weight is between 40 and 115 kg.I am over 40 years old.I can walk 3 meters and sit down without help from another person.I have been diagnosed with IBM according to ENMC criteria and have the necessary test results.
- Group 1: 2.0 mg/kg ABC008
- Group 2: 0.5 mg/kg ABC008
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there vacancies available for participants in this research?
"Per the records available on clinicaltrials.gov, this trial is still searching for enrollees. The initial publication of the research was February 28th 2023 with a subsequent update occurring March 8th in the same year."
How many healthcare centers are participating in the trial currently?
"Nine clinical trial sites, including those located in New Haven, Boston and New york are currently participating. Prospective participants should prioritize the closest location to minimize required travelling for their participation."
What is the aggregate number of participants involved with this trial?
"Abcuro, Inc., the trial sponsor, intends to enroll 231 eligible patients at two of its sites: Yale School of Medicine in New Haven and Neuromuscular Diagnostic Center - Massachusetts General Hospital in Boston."
What is the aim of this clinical experiment?
"From baseline to the end of the trial, which will last approximately 76 weeks, researchers are primarily interested in assessing ABC008's safety and tolerability when taken recurrently by IBM patients at two dose levels. Secondary objectives include measuring changes in quadriceps strength via dynamometry, recording treatment-emergent adverse events within 24 hours post-administration of study medications, and counting occurrences of side effects that necessitate discontinuation from the trial."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger